A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Leukemia & lymphoma Year : 2022

A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia

Abstract

We report efficacy, safety and biomarker data from a phase-II study evaluating atezolizumab (eight 21-day cycle as induction therapy) in combination with obinutuzumab in patients with relapsed/refractory mantle cell lymphoma (MCL, n = 30) or Waldenström's macroglobulinemia (WM, n = 4), and in combination with rituximab in patients with marginal zone lymphoma (MZL, n = 21). All patients received atezolizumab monotherapy as maintenance for ≤10 cycles. Objective response rates at end of induction were 16.7% (MCL) and 42.9% (MZL), with no responses in WM. Median duration of response was 6.8 months (range 5.7-not estimable) for MCL and not reached for MZL. Treatment-emergent adverse events (TEAEs) occurred in 93.3%, 95.2% and 100% of MCL, MZL and WM patients, respectively. One fatal TEAE (pneumonia) occurred in each of the MCL and MZL groups. Biomarker analysis highlighted the importance of characterizing the immune environment to optimize efficacy of immunotherapy regimens.Trial registration details: EudraCT: 2016-003579-22.
Embargoed file
Embargoed file
Visibility date is undetermined

Dates and versions

inserm-03561708 , version 1 (08-02-2022)

Identifiers

Cite

Panayiotis Panayiotidis, Gayane Tumyan, Catherine Thieblemont, Vadim Ptushkin, Ana Marin-Niebla, et al.. A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia. Leukemia & lymphoma, 2022, pp.1-12. ⟨10.1080/10428194.2021.2015765⟩. ⟨inserm-03561708⟩
77 View
25 Download

Altmetric

Share

Gmail Facebook X LinkedIn More